Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07144163 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 68 → 72 locations
    • Eligibility criteria expanded, about 11 words
    • Study description revised
  2. Trial sites expanded: 63 → 68 locationsv11
  3. Trial sites expanded: 55 → 63 locationsv10
  4. Trial sites expanded: 45 → 55 locationsv9
  5. Trial sites expanded: 36 → 45 locationsv8
  6. Trial sites expanded: 26 → 36 locationsv7
  7. Trial sites expanded: 17 → 26 locationsv6
  8. Study sites: 8 to 17v5
  9. Study sites: 5 to 8
    • Eligibility criteria expanded, about 1 word
    v4
  10. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2025 to Dec 11, 2025
    • Site details revised at 5 of 5 sites
    v3
  11. Study sites: 0 to 5v2
  12. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.
Trial Details
NCT Number NCT07144163
Lead Sponsor Crinetics Pharmaceuticals Inc.
Conditions
(from sponsor)		 Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Related terms Adrenal Hyperplasia, Congenital
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov